WO2023179905 - COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER
National phase entry:
Publication Number
WO/2023/179905
Publication Date
28.09.2023
International Application No.
PCT/EP2023/000022
International Filing Date
23.03.2023
Title **
[English]
COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER
[French]
COMBINAISON DE 5-AMINO-2,3-DIHYDRO -1,4-PHTALAZINEDIONE ET D'UN ESTER D'ACIDE FUMARIQUE
Applicants **
METRIOPHARM AG
Europaallee 41
8021 Zürich, CH
Inventors
BRYSCH, Wolfgang
Rabenhorststr. 7
13505 Berlin, DE
SCHUMANN, Sara
Hauptstr. 1
14554 Seddiner See, DE
BREMBECK, Felix
Kurfürstenstr. 126A
10785 Berlin, DE
LUDESCHER, Beate
Dannenwalder Weg 58
13439 Berlin, DE
VON WEGERER, Jörg
Ruhlebener Str. 20
13597 Berlin, DE
Priority Data
22000080.6
25.03.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1320 | |
| EPO | Filing, Examination | 3932 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9128 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application relates to a combination of 5-amino-2,3-dihydro-1,4- phthalazinedione or one of its pharmaceutically acceptable salts and at least one fumaric acid ester or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt in said pharmaceutical combination. Pharmaceutical compositions and advantageous formulation techniques are disclosed.[French]
La présente invention concerne une combinaison de 5-amino-2,3-dihydro -1,4-phtalazinedione ou d'un de ses sels pharmaceutiquement acceptables et d'au moins un ester d'acide fumarique ou d'un sel pharmaceutiquement acceptable de celui-ci. En particulier, l'invention concerne l'utilisation de sel de sodium de 5-amino-2,3-dihydro -1,4-phtalazinedione dans ladite combinaison pharmaceutique. L'invention concerne également des compositions pharmaceutiques et des techniques de formulation avantageuses.